Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy.
What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ?
Ask for a high quality version of this poster :
Ask for high quality link by putting your email below
View and download on Slideshare (low quality) https://fr.slideshare.net/hcspharma/a-groundbreaking-3d-cell-culture-technology-for-hcs-biomimesys-hydroscaffold
Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.
We are delighted to announce that a very interesting study using BIOMIMESYS® to study the metastasis of breast cancer has been published in Experimental Hematology & Oncology Journal (Impact factor 11,4). This article untitled “ProNGF Read more…
HCS Pharma announces the closure of the “MIMLIVERonChip” project, funded by the French National Research Agency (ANR, project ANR 19 CE19-0020) and coordinated by BMBI Biomechanics and Bioengineering joint research unit (UTC/ CNRS), headed by Read more…
2 Comments
SLAS Washington 2019: the evidence of 3D culture for drug discovery! | HCS Pharma · February 14, 2019 at 1:57 pm
[…] BIOMIMESYS® technology in a talk during the tutorial organized by Molecular Devices (see our poster here – if you want the presentation, please contact […]
Feedback from TERMIS congress in Nantes! by HCS Pharma | HCS Pharma · September 16, 2019 at 5:33 pm
[…] research. There we presented 3 posters – that you can find on our website! – about BIOMIMESYS® product range, about iPSC-derived hepatocytes in BIOMIMESYS® Liver, and about BIOMIMESYS® for organ-on-chip […]